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Abstract Arsenic trioxide (As2O3) induces clinical remission in
acute promyelocytic leukemia, even in all-trans retinoic acid-
refractory cases, with minimal toxicity at low (1^2 WM)
concentration. We exposed various neuroblastoma cell lines to
As2O3 at a concentration of 2 WM: as a result, seven of 10
neuroblastoma cell lines underwent apoptosis characterized by
morphological changes and nucleosomal DNA fragmentation.
As2O3-induced apoptosis in neuroblastoma cells was shown to
occur through the activation of caspase 3, as judged from
Western blot analysis and apoptosis inhibition assay. It seemed
that the sensitivity of neuroblastoma cells to As2O3 was inversely
proportional to their intracellular level of reduced glutathione.
Taken together these results indicate that As2O3 would be a
candidate as a therapeutic agent for treatment of neuroblastoma,
which is a solid tumor, not only by systemic therapy but also by
local therapy.
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1. Introduction
Recently, arsenic trioxide (As2O3) at a low dose (1^2 WM)
was shown to have a therapeutic e¡ect against acute promye-
locytic leukemia (APL) cells, even in patients resistant against
all-trans retinoic acid (ATRA) or conventional chemotherapy
[1,2], by induction of apoptosis of APL cells [2]. As for the
mechanism of As2O3-induced apoptosis on APL cells, arsenic
induces apoptosis directly by the down-regulation of Bcl-2
protein and modulation of promyelocytic leukemia (PML)-
retinoic acid receptor K (RARK) fusion protein speci¢c for
APL cells with the t(15;17) translocation [3] and/or modula-
tion of PML protein [4]. Furthermore, the activation of cas-
pases was also involved in As2O3-induced apoptosis in APL
cells [2].
Wang et al. reported that As2O3 and melarsoprol, the or-
ganic arsenical, brought about apoptosis in myeloid leukemia
cell lines such as HL60, U937, and KG-1 through the down-
regulation of Bcl-2 protein [5]. We also reported that As2O3
induced apoptosis through the down-regulation of Bcl-2 pro-
tein and activation of caspases in B-cell leukemia cell lines [6].
Thus, arsenic is cytotoxic not only to APL cells but also to
other types of leukemia cells by induction of apoptosis
through the down-regulation of Bcl-2 protein and/or activa-
tion of caspases.
Recently, it has been reported that reactive oxygen species
(ROS) such as hydrogen peroxide might play a role as a
mediator to induce apoptosis through the activation of cas-
pase 3 [7,8]. Furthermore, intracellular reduced glutathione
(GSH) content might be an indicator of sensitivity of As2O3
in leukemia cells [9], because arsenic toxicity results from
forming reversible bonds with thiol groups of regulatory pro-
teins including GSH [10].
On the other hand, chronic toxication of arsenic com-
pounds has been evidenced in lung and skin cancers, non-
cancerous skin lesions, peripheral nerve e¡ects, and cardiovas-
cular changes [11]. Especially the nervous system e¡ects prog-
ress to become widespread.
Based on these ¢ndings, we exposed 10 various neuroblas-
toma cell lines to 2 WM As2O3 and assessed its apoptotic
e¡ect.
2. Materials and methods
2.1. Reagents
As2O3 (Sigma) prepared in phosphate-bu¡ered saline (PBS) at a
concentration of 1 mM was used at a concentration of 2 WM in
RPMI 1640 culture medium supplemented with 10% (v/v) heat-inac-
tivated fetal bovine serum (FBS). N-Acetylcysteine (NAC) (Sigma)
was dissolved in PBS and used at a concentration of 10 mmol/l.
2.2. Cell culture and morphological study
Human cell lines were grown in RPMI 1640 medium supplemented
with 10% (v/v) heat-inactivated FBS (CSL Ltd.) and 2 mM L-gluta-
mine under an atmosphere of 95% air and 5% CO2 at 37‡C.
The neuroblastoma cell lines used in this study were the following:
SH-SY5Y, LA-N-1, LA-N-2, LA-N-5, NB9, NB16, NB19, IMR-32,
TNB-1, and CHP134 [12]. Exponentially growing cells were treated
with As2O3 and/or other agents.
For morphological examination of apoptosis, cells were stained
with Hoechst 33342 (5 Wg/ml) at 37‡C for 30 min and observed by
£uorescence microscopy.
2.3. Assessment of nucleosomal DNA fragmentation
Cellular DNA was extracted from whole cells. RNase was added to
the DNA solution at a ¢nal concentration of 20 Wg/ml, and the mix-
ture was incubated at 37‡C for 30 min. Electrophoresis was performed
on a 2.0% agarose gel. After electrophoresis, DNA was visualized by
ethidium bromide staining.
2.4. Western blot analysis
The activation of caspases such as caspase 1, 3, 8 and 9, and the
change of amount of Bcl-2 family members such as Bcl-2 and Bax
were studied by Western blot analysis. Each cell protein lysate was
prepared in lysis bu¡er (2UPBS, 0.1% SDS, 1% Nonidet P-40, 0.5%
sodium deoxycholate, and 0.1 mM phenylmethylsulfonyl £uoride),
and then homogenized with an ultrasonic homogenizer. Thirty micro-
grams of protein of each homogenized sample was separated by SDS-
PAGE using the appropriate percent polyacrylamide gel and electro-
phoresed onto a PVDF membrane (Dupont). After blockage of non-
speci¢c binding sites for 1 h by 5% non-fat milk in TPBS (PBS and
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0.1% Tween 20), the membrane was incubated overnight at 4‡C with
anti-human caspase 1 (Santa Cruz Biotechnology), anti-human cas-
pase 3 (Transduction Laboratories), anti-human caspase 8 (Medical
and Biological Laboratories), anti-human caspase 9 (Santa Cruz Bio-
technology), anti-human Bcl-2 (100) (Santa Cruz Biotechnology) or
anti-human Bax antibody (Medical and Biological Laboratories). The
membrane was then washed three times with TPBS, incubated further
with alkaline phosphatase-conjugated goat anti-mouse antibody
(Promega) at room temperature, and then washed three times with
TPBS. The immunoblot was visualized by use of an enhanced chem-
iluminescence detection kit (New England Biolabs).
2.5. Inhibition of apoptosis by caspase 3 inhibitor
For the study of inhibition of apoptosis, the tetrapeptide caspase 3
inhibitor acetyl-L-aspartyl-L-glutamyl-L-valyl-L-aspartic aldehyde (Ac-
DEVD-CHO) (Peptide Institute) was added 12 h before As2O3 treat-
ment. The optimal concentration of the inhibitor was determined
from dose-response curves for the extent of cell death. Inhibition of
apoptosis by caspase 3-like protease inhibitor was evaluated by the
blockage of the process of nucleosomal DNA fragmentation.
2.6. Measurement of intracellular reduced glutathione
Intracellular GSH content was measured using the Glutathione
Assay Kit (Calbiochem). Brie£y, 2^3U106 cells were homogenized
in 5% metaphosphoric acid using a Te£on pestle (Racine). The homo-
genate was centrifuged and its supernatant was used for GSH meas-
urement according to the manufacturer’s instruction. The pellet was
dissolved in 1 N NaOH and used for the measurement for protein
content [13]. The GSH content was expressed as nmol per mg protein.
The values are the mean of three independent experiments.
3. Results
We used As2O3 at a concentration of 2 WM, which is clin-
ically e¡ective in APL patients [2]. Of the 10 neuroblastoma
cell lines, seven (LA-N-2, LA-N-5, NB16, NB19, CHP143,
TNB-1, and SH-SY5Y) underwent apoptosis as identi¢ed by
nucleosomal DNA fragmentation, which is the biochemical
hallmark of apoptosis, at a concentration of 2 WM As2O3
(Fig. 1 and Fig. 2A). Morphological ¢ndings of apoptosis
such as cell shrinkage, chromatin condensation and nuclear
segmentation were observed in all seven of the a¡ected neuro-
blastoma cell lines (data not shown). As a representative ex-
ample, nucleosomal DNA fragmentation and morphological
characteristics of apoptosis of SH-SY5Y cells after treatment
with 2 WM As2O3 are demonstrated in Fig. 2A and Fig. 3,
respectively. The amount of nucleosomal DNA fragments
gradually increased with the time of exposure to As2O3. West-
ern blot analysis con¢rmed that the apoptotic process elicited
by the exposure to As2O3 was executed through the activation
of caspase 3, which cleaves the inhibitor of caspase-activated
deoxynuclease, after which the caspase-activated deoxynu-
clease degrades the chromosomal DNA to nucleosomal units
(Fig. 4) [14]. The time course of caspase 3 activation corre-
sponded to that of nucleosomal DNA fragmentation. The
formation of nucleosomal DNA fragments was signi¢cantly
blocked by adding caspase 3 inhibitor to the medium, even at
Fig. 1. Nucleosomal DNA fragmentation 72 h after treatment of
nine neuroblastoma cell lines with 2 WM As2O3. Every two lanes
are arranged pairwise. Lane 1 is DNA from untreated cells ; lane 2,
DNA from cells treated with As2O3 for 72 h. Lane M is a DNA
size marker. The names of cell lines are also indicated.
Fig. 2. Arsenic-induced apoptosis (A), its blockage by caspase 3-like
proteases inhibitor (B), and treatment with N-acetylcysteine (C) in
SH-SY5Y cells. 3 Wg of DNA was applied in each lane. Nucleoso-
mal DNA fragmentation was visualized by agarose gel electrophore-
sis. A: Lane M, DNA size marker; lane 1, DNA from untreated
cells ; lane 2, DNA from cells treated with 2 WM As2O3 for 24 h;
lane 3, DNA from cells treated with 2 WM As2O3 for 48 h; lane 4,
DNA from cells treated with 2 WM As2O3 for 72 h. B: The inhibi-
tor, Ac-DEVD-CHO for caspase 3-like proteases, was added 12 h
before As2O3 exposure. The rescue of cell death was evaluated at
72 h after As2O3 exposure by the block of formation of nucleoso-
mal DNA fragments at each concentration of the inhibitor. Lane 1,
DNA from cells treated with 2 WM As2O3 for 72 h (the same sam-
ple as A, lane 4); lane 2, DNA from cells treated with 50 WM inhib-
itor; lane 3, DNA from cells treated with 100 WM inhibitor; lane 4,
DNA from cells treated with 200 WM inhibitor; lane 5, DNA from
cells treated with 400 WM inhibitor. C: 10 mmol/l NAC was added
6 h before As2O3 exposure. The rescue of cell death was evaluated
at 72 h after 2 WM As2O3 exposure or 2 WM As2O3 exposure, to-
gether with 10 mmol/l NAC by the block of formation of nucleoso-
mal DNA fragments. Lane M, DNA size marker; lane 1, DNA
from untreated cells; lane 2, DNA from cells treated with 10 mmol/
l NAC for 72 h; lane 3, DNA from cells treated with 2 WM As2O3
for 72 h; lane 4, DNA from cells treated with 2 WM As2O3 and 10
mmol/l NAC for 72 h.
Table 1
Intracellular reduced glutathione levels of neuroblastoma cells
Cell line LA-N-1 LA-N-2 LA-N-5 NB9 NB16 NB19 IMR-32 CHP134 TNB-1 SH-SY5Y
Glutathione
contenta
50.1 þ 2.25b 41.5 þ 2.36 37.2 þ 2.16 112.6 þ 4.25 36.2 þ 1.92 36.2 þ 2.25 46.3 þ 3.15 39.6 þ 2.12 33.6 þ 2.02 22.5 þ 1.42
aThe glutathione content is expressed as nanomoles per miligram protein.
bThe values was a average of the values in three independent experiments. Mean þ S.D. is given (n = 6).
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a concentration of 50 WM, before treatment with As2O3 (Fig.
2B).
Activation of caspase 3 was found in all seven of the cell
lines that showed nucleosomal DNA fragmentation, as judged
from the results of Western blot analysis (data not shown).
Activation of caspase 9 and caspase 8, which work upstream
of caspase 3, was not found in As2O3-induced apoptosis of
SH-SY5Y cells by Western blot analysis. In addition, neither
down-regulation of Bcl-2 protein nor up-regulation of Bax
protein was found. Thus, As2O3 is able to induce apoptosis
in the majority of various neuroblastoma cell lines tested in
this study through the activation of caspase 3.
The content of intracellular GSH was signi¢cantly high in
cells of LA-N-1 and NB9, which did not undergo apoptosis,
but very low in cells of SH-SY5Y, in which apoptosis was
easily induced by As2O3 (Table 1). With regard to these three
cell lines, the intracellular level of GSH was inversely corre-
lated with the susceptibility to apoptosis elicited by exposure
to As2O3. To examine the relationship between the content of
intracellular GSH and As2O3-induced apoptosis, we treated
SH-SY5Y cells with 2 WM As2O3 alone or together with 10
mmol/l NAC (a thiol-containing antioxidant capable of di-
rectly inactivating ROS as well as inducing GSH production)
for 72 h. In Fig. 2C, NAC was able to protect SH-SY5Y cells
from As2O3-induced DNA ladder formation completely.
4. Discussion
In the present study, we showed that As2O3 at a low dose (2
WM) induced apoptosis in seven of 10 neuroblastoma cell
lines. As2O3 induces clinical remission in ATRA-resistant
APL patients [1,2], which indicates that the mechanisms of
apoptosis induced by As2O3 and ATRA are di¡erent. Then,
the plasma concentration of As2O3 was sustained at 1^2 WM,
which is thought to be a therapeutic and cancer-selective
range in treating APL cells with minimal toxicity [1]. Earlier,
we had accepted that As2O3 induces apoptosis in NB4 cells
which have t(15;17) translocation by degrading PML-RARK
fusion protein, which is directly associated with the pathogen-
esis of APL [3] and further seems to target especially to PML
protein [4]. However, NAC and lipoic acid, which increase the
content of GSH, blocked As2O3-induced apoptosis in NB4
cells regardless of inducing degradation of the PML-RARK
chimeric protein [9]. Moreover, our results in this study indi-
cate that As2O3 is also e¡ective against solid tumors of neuro-
blastoma cells which have no PML-RARK chimeric protein.
The GSH redox system is known to modulate the growth-
inhibitory e¡ects of arsenicals [10]. Recently, Dai et al. re-
ported that the sensitivity to As2O3-induced apoptosis in the
several cell lines including NB4 cells was inversely correlated
with the intracellular GSH content [9], which determines the
sensitivity of cancer cells toward As2O3. In cells of low GSH
content, because arsenic binds to sulfhydryl group containing
compound such as GSH, the capacity to eliminate ROS is
decreased, with the result that intracellular levels of ROS in-
crease and they cause the activation of caspase 3 [7,8]. In our
cases, cells with a high level of intracellular GSH such as LA-
N-1 cells and NB9 cells did not undergo apoptosis, while cells
with a low level of intracellular GSH such as SH-SY5Y cells,
LA-N-5 cells, and TNB-1 cells were susceptible to undergo
apoptosis. Moreover, NAC completely prevents the DNA lad-
der formation caused by exposure to As2O3 in SH-SY5Y cells.
Thus, the intracellular GSH content would be a good indica-
tor for application of As2O3 to various kinds of cancer cells.
Although it was reported by us [6] and others [3,5] that
activation of caspase 3 was accompanied by the down-regu-
lation of Bcl-2 in As2O3-induced apoptosis, we did not ob-
serve down-regulation of Bcl-2 in adherent SH-SY5Y cells by
the analysis of Western blot. Furthermore, we did not ¢nd up-
regulation of Bax and activation of caspase 9 which is asso-
ciated with cytochrome c release from mitochondria. In sam-
ples from £oating cells like leukemia cells, contamination of
apoptotic cells which would not generate proteins actively for
cell proliferation should be considered to assess the down-
regulation of Bcl-2 by the analysis of Western blot, because
it is unclear whether Bcl-2 contributes to the induction of
apoptosis in early phase.
Based on these ¢ndings, it is considered that As2O3-induced
apoptosis could be mediated by the common pathway in the
process of cell death. It is still not clear whether As2O3 mod-
ulates the GSH redox system directly, but from our present
results and previous report [6], arsenic most likely functions as
a caspase 3 activator.
Thus, our results raise the possibility that As2O3 will be
e¡ective even against a solid tumor such as neuroblastoma
and warrant clinical trials for patients with neuroblastomas
not only by systemic therapy but also by local therapy.
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Fig. 4. Western blot analysis of caspase 3 in SH-SY5Y cells treated
with 2 WM As2O3. 30 Wg of protein of the homogenate was electro-
phoresed on a 12% SDS-polyacrylamide gel. Lane 1, untreated cells ;
lane 2, cells treated with 2 WM As2O3 for 24 h; lane 3, cells treated
with 2 WM As2O3 for 48 h; lane 4, cells treated with 2 WM As2O3
for 72 h. Note that anti-human caspase 3 antibody recognized both
the 32 kDa proenzymes (open square) and their 17 kDa active
forms (open triangle).
Fig. 3. Morphological aspects of Hoechst 33342-stained cells. Un-
treated SH-SY5Y cells (A) and SH-SY5Y cells treated with 2 WM
As2O3 for 48 h (B).
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